

Biosimilars LatAm – Brazil 2025
As a platform for advancing access to biosimilars in Brazil, this forum convenes senior executives and key stakeholders from the pharmaceutical and regulatory sectors to examine strategies for consolidating Brazil’s leadership in the global biosimilars market. Through engaging panels, expert presentations, and networking sessions, the event explores the role of international alliances, the contributions of ANVISA and academic institutions, and solutions for overcoming regulatory and market challenges to ensure global distribution.
Key Objectives:
– Analyze how alliances with international entities facilitate entry into new markets.
– Discuss the role of ANVISA and universities in fostering research and developing bioprocess talent.
– Address strategies for navigating regulatory and market challenges to enable global distribution of biosimilars.

Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Plan Your 1-to-1 Meetings with JackLeckerman Web App
Speaker Board

Priscila Pereira Menino
Lawyer Partner

Sarem Hailemariam
Platform Development Specialist

Rafael Menezes
Senior Regional Marketing Manager

Rogério Almeida
R&DI Vice President

Jose Salvador Velasco
Executive Director

Gilbert Silveira
Senior Bioprocess Application Specialist

Patrícia Guimarães
Regional Sales Manager Latam

Stacey Ricci
Director Scientific Review Staff OTBB

Silvia Giaffone
Sr. Manager, Global Safety - Pharmacovigilance lead for Brazil Hub

Carlos Diaz Tufinio
Associate Professor

Edwin Cruz
Manager of Process Consulting

Uilberson Silva
RD&I Director

Rafael Costa
Strategy and Business Executive Director

Anderson Vezali Montai
Manager of Biologic Product Office

Ramses Gamboa
Business Development Manager

Flavio Spegiorin Ramos
Partner

Thiago Mares Guia
Executive Vice President
Program at a Glance
Understanding INN Suffixes for New Antibodies
The purpose and structure of International Nonproprietary Name (INN) suffixes in the naming of new antibodies will be clarified. Emphasis will be placed on their role in pharmacovigilance, product differentiation, and regulatory compliance across global markets.
Aligning Brazilian Compliance with EMA Standards for European Market Access and Regulatory Update
Explore strategies for aligning Brazilian biosimilars with EMA regulatory standards
Building a Sustainable Biosimilars Ecosystem in Brazil
Analyze how alliances with foreign entities facilitate entry into new markets.This panel will explore how Brazil can develop a sustainable biosimilars ecosystem by combining local innovation, international regulatory compliance (EMA/FDA), and strategic global partnerships.
Public-private collaboration models, national production incentive policies, and access strategies will be discussed to ensure long-term competitiveness in both domestic and international markets.
Strategic Alliances for Brazilian Biosimilars’ Global Expansion
Analyze how alliances with foreign entities facilitate entry into new markets.
Regulatory Synergy in Brazil’s Biosimilars Landscape
Highlighting how innovation in R&D, combined with streamlined regulatory pathways, can accelerate biosimilar development and market entry within Brazil.
Strategic Actions and Recommendations for Manufacturers
Full Programme in the PDF Agenda
Download Agenda

Sponsors
Photo Gallery from Previous Events
